August 28, 2017 • Ben Hirschler
AstraZeneca's blood-thinner Brilinta cuts the risk of cardiovascular death by 29 percent in patients with a history of past heart attacks who keep taking it beyond the standard 12-month initial period, according to new clinical trial data. The findings are being presented this week at the European Society of Cardiology congress, are from a sub-analysis of the Pegasus clinical trial, which first reported positive results in 2015. The trial studied subjects who had a heart attack within the past one to three years and was designed to prove the value of extended use of Brilinta, which is a key product for AstraZeneca. The sub-analysis also showed a risk reduction of 20 percent in all causes of death, while bleeding rates were consistent with the drug's safety profile, AstraZeneca said on Thursday. This article was provided by Reuters.
The findings are being presented this week at the European Society of Cardiology congress, are from a sub-analysis of the Pegasus clinical trial, which first reported positive results in 2015.
The trial studied subjects who had a heart attack within the past one to three years and was designed to prove the value of extended use of Brilinta, which is a key product for AstraZeneca.
The sub-analysis also showed a risk reduction of 20 percent in all causes of death, while bleeding rates were consistent with the drug's safety profile, AstraZeneca said on Thursday.
This article was provided by Reuters.
Please log back in before proceeding.
There was an error logging in. Please try again.
Congrats! You are now logged in. Your exam is being submitted.